Icosavax Inc (ICVX) Stock
ICVX is no longer traded. Icosavax was delisted from the Nasdaq in February 2024.
Prices on this page are historical; the last trade was February 16, 2024 at $15.31.
Icosavax stock price history
ICVX final trading statistics
- Final close
- $15.31
- Final trading day
- Feb 16, 2024
- Market cap at delisting
- $769.04M
- Shares outstanding
- 50.23M
- Final 52-week range
- $4.75 – $16.11
- Avg. volume (final 3 mo.)
- 1,197,080
- All-time high (split-adj.)
- $40.25 · Aug 2021
- All-time low (split-adj.)
- $2.32 · Nov 2022
- Return since IPO
- -56.2%
- Beta
- 1.28
- Book value / share
- $4.64
- Price / book
- 3.30
Icosavax annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$96.7M | -$1.63 |
| FY2022 | $582.0K | -$88.5M | -$2.31 |
| FY2021 | $7.80M | -$68.0M | -$5.13 |
| FY2020 | $1.62M | -$19.2M | -$2.11 |
| FY2019 | $0.00 | -$5.2M | -$1.76 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Icosavax Inc
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
Icosavax stock FAQ
What happened to Icosavax stock?
Icosavax stock was delisted from the Nasdaq. Its final close was $15.31 on February 16, 2024.
Is ICVX stock still trading?
No. ICVX was delisted from the Nasdaq in February 2024 and no longer trades on a U.S. exchange.
What was the last price of ICVX stock?
ICVX closed at $15.31 on its final trading day, February 16, 2024, for a market value of about $769.04M.
What were Icosavax's revenue and earnings in its last full fiscal year?
Icosavax reported revenue of $0.00 and net income of -$96.7M in fiscal 2023, its last full year as a public company.
When did Icosavax go public?
Icosavax Inc stock began trading on July 29, 2021.